Background: Central obesity is a risk factor for cardiovascular and metabolic disorders including diabetes, hypertension and dyslipidemia. Index of central obesity (ICO) , defined as ratio of waist circumference and height, has been earlier proposed as a screening tool for central obesity and metabolic syndrome. We report the prevalence of self-reported central obesity based on ICO in a nationwide community screening program from data collected by the Research Society for the Study of Diabetes in India (RSSDI) as part of the Defeat Diabetes Campaign. Methodology: Data collected from the One Nation, One Day, One Million Tests campaign by RSSDI was retrospectively analyzed. A data of 105481 adults was included in the analysis (69483 were males and 35956 females) . ICO (calculated from self-reported waist size & height) cutoff of 0.5 was used to estimate the prevalence of central obesity in the Indian population. Results: 69.3% (n=73072) of the overall cohort was found to be having central obesity, prevalence being slightly higher among females (75.1%) compared to males (66.3%) . Prevalence of central obesity was higher among diabetic subjects (77.8%) compared to the nondiabetes population (64.6%) . Prevalence of central obesity was higher among females with diabetes (81.5%) compared to males (75.9%) . Prevalence of central obesity was 60.8% and 71.8% in males and females without diabetes respectively. Conclusions: Central obesity is highly prevalent in the Indian population, with prevalence being slightly higher among females compared to males and among people living with diabetes when compared to nondiabetes subjects. As central obesity is a known risk factor for CVD and Metabolic disorders - strategies and interventions directed to address central obesity may be developed and implemented to prevent the future incidence of CVD and Metabolic disorders including diabetes. ICO is a simple screening tool in population dense and resource limited settings. Disclosure B.D.Saboo: None. S.Chittawar: None. A.Nanditha: None. R.M.Parikh: None. A.Gupta: Speaker's Bureau; Lupin Pharmaceuticals, Inc., Medtronic, Novartis AG, Novo Nordisk, Sanofi. V.K.Ch: None. B.M.Makkar: None. S.Agarwal: Speaker's Bureau; Novo Nordisk, Roche Diabetes Care, Sanofi, USV Private Limited. P.M.Chawla: Speaker's Bureau; Biocon, Boehringer Ingelheim International GmbH, Eris Lifesciences Ltd., Novo Nordisk, Sanofi. R.R.Kovil: None. S.Bhattacharyya: None.

中文翻译：

---

1517-PUB：印度男性和女性在全国社区筛查计划中自我报告的中枢性肥胖患病率

背景：向心性肥胖是心血管和代谢疾病（包括糖尿病、高血压和血脂异常）的危险因素。中心性肥胖指数（ICO），定义为腰围和身高的比率，较早被提出作为中心性肥胖和代谢综合征的筛查工具。我们根据印度糖尿病研究协会 (RSSDI) 作为战胜糖尿病运动的一部分收集的数据，在全国社区筛查计划中报告了基于 ICO 的自我报告中心性肥胖的患病率。方法：回顾性分析了 RSSDI 从一国一日一百万次测试活动中收集的数据。分析包括 105481 名成年人的数据（69483 名男性和 35956 名女性）。ICO（根据自我报告的腰围尺寸和身高计算）截止值为 0。5 用于估计印度人群中中心性肥胖的患病率。结果：发现整个队列中有 69.3% (n=73072) 患有中心性肥胖，女性 (75.1%) 的患病率略高于男性 (66.3%)。与非糖尿病人群（64.6%）相比，糖尿病患者（77.8%）的中心性肥胖患病率更高。与男性（75.9%）相比，女性糖尿病患者的中心性肥胖患病率（81.5%）更高。在没有糖尿病的男性和女性中，中心性肥胖的患病率分别为 60.8% 和 71.8%。结论：向心性肥胖在印度人群中非常普遍，女性的患病率略高于男性，糖尿病患者的患病率略高于非糖尿病患者。由于中心性肥胖是 CVD 和代谢紊乱的已知风险因素 - 可以制定和实施针对中心性肥胖的策略和干预措施，以防止未来发生 CVD 和代谢紊乱，包括糖尿病。ICO 是人口密集和资源有限环境中的简单筛选工具。披露 BDSaboo：无。S.Chittawar：没有。A.Nanditha：没有。RMParikh：没有。A.Gupta：议长局；Lupin Pharmaceuticals, Inc.、美敦力、诺华、诺和诺德、赛诺菲。VKCh：没有。BMMakkar：没有。S.Agarwal：议长局；诺和诺德、罗氏糖尿病护理、赛诺菲、USV 私人有限公司。PMChawla：议长局；Biocon、勃林格殷格翰国际有限公司、Eris Lifesciences Ltd.、诺和诺德、赛诺菲。RRKovil：没有。S.Bhattacharyya：没有。